Abstract

The present application relates to uses of flunarizine and a method for controlling the number of intercellular mitochondria. The uses include use of the flunarizine in removing intracellular mitochondria, and use of the flunarizine in the preparation of a medicament for preventing and/or treating a disease associated with mitochondrial abnormality. The method includes: controlling the total amount of mitochondria in the brain by taking the flunarizine; contacting the flunarizine with cells to be treated, and controlling the total amount of the intercellular mitochondria based on the influence of the contact time on the removal amount of the mitochondria.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A method for regenerating a humoral immunity system. A pluripotent stem cell is used for expressing a RUNX1 gene, a HOXA9 gene and an LHX2 gene to efficiently obtain B cell seeds after in vitro induction differentiation, and after transplantation, a complete humoral immune system can be reconstructed in an animal in which the humoral immune system is missing. According to the method, an antigen-specific antibody immune response can be realized, a specific high-affinity antibody can be generated against an antigen, and immunological memory can be produced. Meanwhile, the reconstructed immune system is safe, and carries no risk of tumorigenicity.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided are an arylimidazolyl isoxazole compound, and a preparation method therefor and a use thereof. The structure of the arylimidazolyl isoxazole compound is as represented by formula I. The provided arylimidazolyl isoxazole compound can effectively degrade CBP and p300 proteins, and has an excellent anti-cancer effect.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

Provided in the present invention are thyroid hormone receptor β (TRβ) agonist compounds (I), a preparation method therefor, and the use thereof. The compounds and pharmaceutically acceptable salts, esters, amides or carbamates, and isomers, racemates, prodrugs, co-crystal complexes or solvates and the like of same all can be used as thyroid hormone receptor β agonists for use. In addition, the prepared thyroid hormone receptor β agonists have good activation effect on wild-type and mutant-type thyroid hormone receptors β while having weak effect or basically having no effect on thyroid hormone receptor α (TRα) and prolyl hydroxylase (PHD2) targets, thereby achieving relatively good selectivity. Therefore, the compounds can be used in the prevention or treatment of related diseases mediated by thyroid hormone receptors β.

IPC Classes  ?

• C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61P 3/06 - Antihyperlipidemics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/24 - Antidepressants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 35/00 - Antineoplastic agents
• A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• A61P 5/16 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

Provided are an isolated circular nucleic acid molecule and a pharmaceutical composition. The nucleotide sequence of the isolated circular nucleic acid molecule is set forth in SEQ ID NO: 1. The pharmaceutical composition comprises: a reagent for inhibiting the expression or activity of a circular nucleic acid molecule, the circular nucleic acid molecule having a nucleotide sequence set forth in SEQ ID NO: 1.

IPC Classes  ?

• C12N 15/12 - Genes encoding animal proteins
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/867 - Retroviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided are a polypeptide translated by a circular RNA Circ-ACE2 and an application thereof, the circular RNA molecule comprising at least one of the following sequences: 1) an RNA sequence as set forth in SEQ ID NO: 1; 2) an RNA sequence having at least 70% identity with 1), preferably an RNA sequence having at least 80% identity with 1), preferably an RNA sequences having at least 85% identity with 1), preferably an RNA sequence having at least 90% identity with 1), preferably an RNA sequence having at least 95% identity with 1), and more preferably, an RNA sequence having at least 99% identity with 1).

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to an adenovirus vector vaccine for preventing African swine fever and use thereof. Provided is a nucleic acid molecule, comprising the following optimized genes: p30 gene, p54 gene, CD2v gene, p72 gene, and p72 C gene. The nucleic acid molecule can express a p30 protein, a p54 protein, a CD2v protein, and a p72 protein, can express p30, p54, CD2v, and p72 antigens after immunizing an organism, generates specific antibodies and cellular immune responses against African swine fever virus antigens, can effectively protect the organism from being infected by African swine fever virus, and can be used to prepare a drug for preventing the infection caused by the African swine fever virus, to prepare a drug for preventing and/or treating African swine fever, to prepare a product for detecting the African swine fever virus, to prepare a product for diagnosing African swine fever, and to prepare a gene function regulator.

IPC Classes  ?

• C12N 15/34 - Proteins from DNA viruses
• C12N 15/861 - Adenoviral vectors
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Provided is a genetically engineered γδT cell, which is characterized in that a high-affinity αβTCR gene is transferred into the γδT cell, and the affinity of the high-affinity αβTCR to the specific pMHC thereof is at least two times of that of a wild-type αβTCR corresponding thereto. Further provided are a use of and a preparation method for the γδT cell.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors

Abstract

Provided are a vesicular stomatitis virus vector, which comprises sgVSV (△L/L) and sgVSV (△G/G), which can load and express an exogenous gene, is lower in toxicity relative to a wild type strain, has a smaller likelihood of recombinant mutation relative to an existing srcVSV vector, has a larger exogenous gene loading capacity, and can be used for vaccine development, gene delivery drugs, and treating tumors. Further provided is a vesicular stomatitis virus sgVSV (ΔG/GδRBD) carrying a novel coronavirus RBD gene.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides use of citrulline or a pharmaceutically acceptable salt thereof in the preparation of a medicament, a method for improving the activity of matrix metalloproteinase 7, a method for up-regulating the expression of the gene encoding matrix metalloproteinase 7, a pharmaceutical composition for improving immunity or preventing or treating anxiety disorder, and a method for preventing or treating anxiety disorder and improving immunity.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 37/04 - Immunostimulants
• A61P 25/22 - Anxiolytics

Abstract

An chip for integrated tumor cell behavior experiments, which comprises a functional area I, a functional area II, a functional area III, a functional area IV and a functional area V, wherein the functional area I comprises a cell invasion 3D co-culture plate (400) for cell invasion experiments; the functional area II comprises a cell migration culture hole (500) for cell migration experiments; the functional area III comprises a cell proliferation single-cell culture hole (600) for tumor single-cell culture; the functional area IV comprises an angiogenesis 3D co-culture plate (700) for tumor-related angiogenesis experiments; and the functional area V comprises a tumor single-cell culture hole (803), a matrix glue groove (805) and a tumor cell attraction factor hole (801) connected by matrix glue for tumor single-cell migration or invasion experiments. The single-cell culture, micro-fluidic and 3D culture techniques are comprehensively used in the chip, such that the experiment process is obviously simplified, the experiment efficiency is improved, and the obtained experiment result has a higher accuracy and repeatability.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present application provides a dendron-like lipid compound, a liposome, a lipid complex, and a lipid nanoparticle and a use thereof. The dendron-like lipid compound is selected from any one of structures represented by formulas I-III. The present application provides a series of dendron-like lipid compounds of novel structures; and liposomes prepared from the lipid compounds provided by the present application have uniform particle size distribution, carry negative charges on the surfaces, and have low cytotoxicity. The lipid nanoparticle provided by the present application can specifically target and deliver active substances to cells, tissues or organs, thereby realizing targeted delivery of the active substances.

IPC Classes  ?

• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups

Abstract

A combination of a m6A RNA methylase inhibitor and an immune checkpoint inhibitor for treating tumors. The combination therapy is that the combination of a tumor immunotherapeutic agent and STM2457 or a derivative thereof is used for treating tumors comprising melanomas and ovarian cancer. The new combination therapy of anti-tumor drugs has great significance in temrs of drug development and clinical treatment of melanomas or ovarian cancer.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are media and methods for producing human cells and tissues from teratoma, organoids and embryoid bodies. The culture media can be used to culture mammalian pluripotent stem cells (PSCs), are chemically defined, and comprise basal media for culturing stem cells supplemented with a S-adeosylhomocysteine hydrolase (SAH)/Polycomb repressive complexes (PRC)/EZH2 inhibitor and a histone deacetylase (HDAC) inhibitor. With the culture media, primate (human and non-human) PSCs can be converted to preimplantation ICM-like cells (naïve PSCs/ICLCs) or 8-cell embryo-like cells (8CLCs). These naïve PSCs/ICLCs and 8CLCs can generate human tissues and cells through teratomas, organoids and EBs differentiation. These tissues and cells can be purified and function as a good source for transplantation and clinical or scientific research.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells

Abstract

Provided herein is a method for reprogramming or inducing presomitic mesoderm progenitor cells from urine cells, a somitoid structure formed by the presomitic mesoderm progenitor cells and uses thereof.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61P 19/00 - Drugs for skeletal disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present application relates to a benzo five-membered nitrogen heterocyclic compound and an application thereof. The benzo five-membered nitrogen heterocyclic compound has the structure represented by formula I. The compound can be used as a compound of RORγ receptor inhibitor. The compound can effectively inhibit RORγ proteins and have good selectivity to other nuclear receptor family proteins. The benzo five-membered nitrogen heterocyclic compound or a pharmaceutical composition thereof provided by the present application can be used for preparing a drug for treating, preventing or ameliorating diseases such as inflammations, autoimmune diseases, cell proliferative disorder diseases, sepsis, cancer, neurodegeneration diseases or viral infections, has a good inhibitory effect on the treatment of tumors, especially the treatment of prostate cancer, and also has an amelioration effect on the treatment of other diseases.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61P 35/00 - Antineoplastic agents
• C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to a use of flunarizine and a method for controlling the number of intercellular mitochondria. The use comprises a use of the flunarizine in the removal of the intracellular mitochondria, and a use of the flunarizine in the preparation of a drug, the drug being used for preventing and/or treating diseases related to mitochondrial abnormalities. The method comprises: taking the flunarizine so that the total amount of mitochondria in the brain can be controlled; enabling the flunarizine to be in contact with cells to be treated, and controlling the total amount of the intercellular mitochondria on the basis of an influence of a contact duration on the removal amount of the intercellular mitochondria.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided is a composition and an application thereof. The composition is used to prepare a medium for inducing differentiation of human pluripotent stem cells to liver precursor cells. By means of screening active components, optimizing the composition ratio and adding a GSK3-beta inhibitor, a Nodal activator, a BMP activator, a BMP inhibitor and a Hedgehog activator, human pluripotent stem cells are induced to differentiate to liver precursor cells. The process is simple and efficient, the content of positive cells is high, and the cost of cell differentiation is reduced. The invention can be used for research and application in drug development and regenerative medicinal treatment, and has broad application prospects.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Disclosed in the present inventions is a fully automatic cell culture system. The fully automatic cell culture system comprises a pre-analysis device, a cell culture device, and a control device. The pre-analysis device comprises an automated centrifuge electrically connected with the control device, a first multi-directional motion transfer mechanism, an automated plate lifting/lowering mechanism, a second multi-directional motion transfer mechanism, a fluorescence imaging identification mechanism, a constant temperature mechanism, an adjustable tilting and rotating mechanism, a solid-liquid separation recovery processing mechanism, and a reagent cryopreservation mechanism. The cell culture device comprises a culture tower electrically connected with the control device and a third multi-directional motion transfer mechanism; the culture tower is used for cell culture and incubation; and the third multi-directional motion transfer mechanism is used for transferring an incubator in the culture tower and a reagent for cell culture in the pre-analysis device. The fully automatic cell culture system in the present invention can implement real-time whole-process monitoring of a cell culture process, automated culture expansion, identification, classification and selection, and automatic data analysis and mining.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

The present application provides a furo-pyridone compound and a use thereof. The furo-pyridone compound provided in the present application can selectively inhibit the combination of a BET family bromodomain and acetylated lysine, can be used as a bromodomain inhibitor, and is used for treating BET related diseases such as cancer and inflammation.

IPC Classes  ?

• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 495/04 - Ortho-condensed systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine

Abstract

Disclosed in the present invention are a bacteria detection system and a bacteria detection method. The bacteria detection system comprises a control module, a mobile module, a drug susceptibility plate fixing apparatus and a detection module, the drug susceptibility plate fixing apparatus being used to fix a drug susceptibility plate holding bacteria to be detected; the detection module comprises a detection apparatus and a light shielding apparatus, the detection apparatus being disposed above the drug susceptibility plate fixing apparatus and used to detect luminescence of bacteria contained in the drug susceptibility plate, and the light shielding apparatus being disposed at a bottom of the detection apparatus and preventing external light from entering the detection apparatus; the mobile module is connected to the detection apparatus and drives the detection apparatus to move; and the control module is electrically connected to the mobile module and the detection apparatus to control actions of the detection apparatus and the mobile module. The present invention targets deficiencies of bacteria detection apparatuses in the prior art, adding a light shielding apparatus to reduce interference of an external light source toward a detection process, thereby ensuring more accurate mycobacterial detection results.

IPC Classes  ?

• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/18 - Testing for antimicrobial activity of a material
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

Disclosed are a construction method of a recombinant drug-resistant Mycobacterium bovis (M. bovis) Bacillus Calmette-Guerin (BCG) strain and a pharmaceutical composition for treating tuberculosis (TB). The construction method includes: using BCG as an original bacterial strain to construct a drug-resistant BCG strain resistant to at least one selected from the group consisting of STR, LFX, EMB, PRO, PAS, and AMK; and further inserting sequence fragments that can express related antigens Ag85b and Rv2628 causing an immune response into a genome of the strain to construct a recombinant drug-resistant BCG strain. The recombinant drug-resistant BCG strain can compete with Mycobacterium tuberculosis (Mtb) for growth, thereby accelerating the death of Mtb. When used in combination with a drug for treating TB, the recombinant drug-resistant BCG strain can further enhance a therapeutic effect for Mtb, and can also avoid re-infection of a patient.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

Provided are a peptide translated by circular RNA Circ-ACE2 and an application thereof, the circular RNA molecule comprising at least one among the following sequences: 1) an RNA sequence represented by SEQ ID NO: 1; 2) an RNA sequence having at least 70% homology with 1), preferably an RNA sequence having at least 80% homology with 1), preferably an RNA sequences having at least 85% homology with 1), preferably an RNA sequence having at least 90% homology with 1), preferably an RNA sequence having at least 95% homology with 1), and more preferably, an RNA sequence having at least 99% homology with 1).

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A method for regenerating a humoral immunity system. A pluripotent stem cell is used for expressing a RUNX1 gene, a HOXA9 gene and an LHX2 gene to efficiently obtain B cell seeds after in vitro induction differentiation, and after transplantation, a complete humoral immune system can be reconstructed in an animal in which the humoral immune system is missing. According to the method, an antigen-specific antibody immune response can be realized, a specific high-affinity antibody can be generated against an antigen, and immunological memory can be produced. Meanwhile, the reconstructed immune system is safe, and carries no risk of tumorigenicity.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/0781 - B cellsProgenitors thereof
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 37/02 - Immunomodulators

Abstract

An chip for integrated tumor cell behavior experiments, which comprises a functional area I, a functional area II, a functional area III, a functional area IV and a functional area V, wherein the functional area I comprises a cell invasion 3D co-culture plate (400) for cell invasion experiments; the functional area II comprises a cell migration culture hole (500) for cell migration experiments; the functional area III comprises a cell proliferation single-cell culture hole (600) for tumor single-cell culture; the functional area IV comprises an angiogenesis 3D co-culture plate (700) for tumor-related angiogenesis experiments; and the functional area V comprises a tumor single-cell culture hole (803), a matrix glue groove (805) and a tumor cell attraction factor hole (801) connected by matrix glue for tumor single-cell migration or invasion experiments. The single-cell culture, micro-fluidic and 3D culture techniques are comprehensively used in the chip, such that the experiment process is obviously simplified, the experiment efficiency is improved, and the obtained experiment result has a higher accuracy and repeatability.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A composition, comprising an O-GlcNAc glycosyltransferase inhibitor and a glycogen synthesis kinase 3β activator. The O-GlcNAc glycosyltransferase inhibitor is selected from 2-[(4-chlorophenyl) imino] tetrahydro-4-oxo-3-(2-tricyclo [3.3. 1.13, 7] decyl-1-ethyl)-2H-1, 3-thiazin-6-carboxylic acid, and the glycogen synthase kinase 3β activator is selected from 3-[[2-(4-fluorophenyl) ethyl] amino]-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2, 5-dione. The composition has an anti-tumor effect, and can improve the anti-tumor effect of vitamin C. A tumor is selected from colon cancer, rectal cancer, or colorectal cancer.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a culture medium for expanding and cultivating human liver progenitor cells and an application thereof. The chemical components of the formula of the described culture medium are clear, no serum is present, and various components thereof cooperate with each other to synergize. The culture medium is used for the long-term expansion and cultivation of liver progenitor cells in vitro and is used for maintaining the dryness thereof, is beneficial in quickly and efficiently obtaining a large number of functional liver cells, and is suitable for clinical hepatocyte transplantation application as well as for the use of hepatocyte reactors in bioartificial livers.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A human glucagon-like peptide-1 receptor (GLP-1R) activator, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and R6 are each independently selected from any one of H, C1-C4 alkyl, mercapto, phosphate, vinyl, or acetyl. The compound of formula I or the pharmaceutically acceptable salt thereof can improve glycolipid metabolism of the tissue cells of a whole body, enhance the oxidative degradation of lipid molecules, inhibit the expression of lipogenic genes, inhibit the activity of acetyl coenzyme A synthetases, reduce the synthesis of triglyceride, improve the synthesis and secretion of glucose-induced insulin, relieve insulin antagonism, relieve the compensatory amplification of pancreatic islets β cells, and improve the survival rate and function of a pancreatic cell in a type-II diabetes sample state.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

The use of a compound in the preparation of a drug. Specifically, the present invention provides the use of a compound represented by formula (I) or a stereoisomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt, prodrug or derivative thereof in the preparation of a drug, wherein the drug is used for the treatment or prevention of small intestinal stem cell senescence.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Provided are media and methods for establishing and maintaining mammalian early embryo-like cells. The culture media can be used to culture mammalian pluripotent stem cells (PSCs), which is chemically defined and comprises basal media for culturing stem cells supplemented with a S-adenosylhomocysteine hydrolase (SAH) /Polycomb repressive complexes (PRC) /EZH2 inhibitor, a histone deacetylase (HDAC) inhibitor and a WNT/β-catenin signaling/tankyrase inhibitor. With the culture media, primate (human and non-human) PSCs can be converted to preimplantation ICM-like cells (ICLCs) or 8-cell embryo-like cells (8CLCs).

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

Abstract

Provided are media and methods for establishing and maintaining mammalian early embryo-like cells. The culture media can be used to culture mammalian pluripotent stem cells (PSCs), are chemically defined, and comprise basal media for culturing stem cells supplemented with a S-adenosylhomocysteine hydrolase (SAH) /Polycomb repressive complexes (PRC) /EZH2 inhibitor and a histone deacetylase (HDAC) inhibitor. With the culture media thereof, primate (human and non-human) PSCs can be converted to preimplantation ICM-like cells (ICLCs) or 8-cell embryo-like cells (8CLCs).

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells
• C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

Abstract

Provided are a method and a system for detecting mtDNA mutations. Specifically, provided is a method for detecting mtDNA mutations in trace cells, comprising: (a) extracting mtDNA in trace cells, the number of trace cells being 1 to 4; (b) performing PCR amplification on different predetermined regions of the mtDNA to acquire amplification products of the different predetermined regions, the different predetermined regions of the mtDNA being superimposed to form the full-length mtDNA; (c) mixing the amplification products of the different predetermined regions to obtain an mtDNA full-length nucleic acid sequencing library; (d) sequencing the nucleic acid sequencing library to obtain sequencing results; and (e) on the basis of the sequencing results, determining mtDNA mutations in the trace cells to be tested.

IPC Classes  ?

• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Disclosed are a transgenic porcine animal and a method of testing therapeutic efficacy of an agent on auto-inflammatory diseases. The transgenic porcine animal comprises a mutation of gene NLRP3, for example, R259W, A351V, or L352P, and a combination thereof.

IPC Classes  ?

• C12N 5/16 - Animal cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided in the present invention is the use of a serum amyloid A inhibitor in the preparation of a drug for treating acute liver injury, acute liver failure or acute-on-chronic liver failure. The serum amyloid A inhibitor comprises any one of an interfering RNA that specifically targets an mRNA sequence of serum amyloid A, a neutralizing antibody that specifically targets serum amyloid A, an antagonistic peptide that specifically targets serum amyloid A or a chemical molecule that specifically targets serum amyloid A, or a combination of at least two thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present application relates to a benzo five-membered nitrogen heterocyclic compound and an application thereof. The benzo five-membered nitrogen heterocyclic compound has the structure represented by formula I. The compound can be used as a compound of RORγ receptor inhibitor. The compound can effectively inhibit RORγ proteins and have good selectivity to other nuclear receptor family proteins. The benzo five-membered nitrogen heterocyclic compound or a pharmaceutical composition thereof provided by the present application can be used for preparing a drug for treating, preventing or ameliorating diseases such as inflammations, autoimmune diseases, cell proliferative disorder diseases, sepsis, cancer, neurodegeneration diseases or viral infections, has a good inhibitory effect on the treatment of tumors, especially the treatment of prostate cancer, and also has an amelioration effect on the treatment of other diseases.

IPC Classes  ?

• C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
• C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 31/12 - Antivirals
• A61P 31/20 - Antivirals for DNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A marker for viral pneumonia and application thereof, applied in the field of drugs. The marker for viral pneumonia is prostaglandin E2 and/or prostaglandin M. By taking the prostaglandin E2 and/or prostaglandin M as a marker for viral pneumonia, the use of a cyclooxygenase II inhibitor can effectively and quickly reduce prostaglandins, thus reversing the progression of common and severe illness, preventing the occurrence of critical illness, and accelerating virus elimination, pneumonia inflammation reduction, and recovery. Once the efficacy is further confirmed, the scope of clinical use of the drug can be expanded, and the treatment method can be applied to clinical diagnosis and treatment, so as to provide a new strategy and diagnosis and treatment method for comprehensive treatment of COVID-19.

IPC Classes  ?

• G01N 33/88 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving prostaglandins

Abstract

Provided is a construction method for a recombinant drug-resistant BCG strain, comprising: using M.bovis BCG as an original bacteria to screen a drug-resistant BCG strain having resistance to least one among streptomycin, levofloxacin, ethambutol, prothiaxamine, aminosalicylic acid and amikacin; and further inserting a sequence fragment that can express the related antigens Ag85b and Rv2628 that cause an immune response, so as to construct a recombinant drug-resistant BCG strain. The recombinant drug-resistant BCG strain can compete with Mtb for growth, thereby accelerating the death thereof, and in combination with a drug for treating tuberculosis, the therapeutic effect thereof for Mtb can be further strengthened.

IPC Classes  ?

• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61P 31/06 - Antibacterial agents for tuberculosis
• C12R 1/32 - Mycobacterium

Abstract

The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to the use of a compound in the preparation of a drug, specifically proposing the use of the compound of formula I or a stereoisomer, nitrogen oxide, solvate, metabolite, or pharmaceutically acceptable salt of the compound of formula I, or a prodrug or derivative thereof in the preparation of a drug, the drug being used for the treatment or prevention of female infertility.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

Provided are a method and a system for detecting mtDNA mutations; specifically provided is a method for detecting mtDNA mutations in trace cells, comprising: (1) extracting mtDNA in trace cells, the number of trace cells being 1-4; (2) performing PCR amplification on different predetermined regions of the mtDNA to acquire amplification products of the different predetermined regions, the different predetermined regions of the mtDNA being superimposed to form the full-length mtDNA; (3) mixing the amplification products of the different predetermined regions to acquire an mtDNA full-length nucleic acid sequencing library; (4) sequencing the nucleic acid sequencing library to acquire sequencing results; and (5) on the basis of the sequencing results, determining mtDNA mutations in the trace cells to be tested.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides use of the mtDNA point mutation rate as a biomarker for ovum quality, and use of an agent for reducing the mtDNA point mutation rate in the preparation of a medicament for improving ovum quality or treating or preventing infertility in women.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

Disclosed are a bifunctional immunomodulator, and a pharmaceutically acceptable salt and pharmaceutical composition thereof. The modulator has a structure represented by formula I. The bifunctional immunomodulator comprises a benzyl phenyl ether molecular skeleton that blocks PD-1/PD-L1 interaction, and a 4-(4-pyrazole) quinoline molecular skeleton that blocks a TGF-β signaling pathway. The two molecular skeletons are connected via molecular chain fragments. The bifunctional immunomodulator can simultaneously block PD-1/PD-L1 interaction and a TGF-β signaling pathway.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/415 - 1,2-Diazoles
• A61P 35/00 - Antineoplastic agents
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Described are 1, 2, 4-substituted azetidine compounds of formula I, as well as pharmaceutical compositions and dosage forms comprising the compounds, and their use as a medicament. The compounds may find use as antibacterial agents, in particular against M. tuberculosis.

IPC Classes  ?

• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 205/02 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
• C07D 205/00 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/415 - 1,2-Diazoles
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

The present application relates to a benzidine compound and an application thereof, the benzidine compound having the structure as shown in formula I below. Further provided in the present application are a pharmaceutically acceptable salt, isomer, racemate, prodrug co-crystal complex, hydrate, and solvate of the compound, as well as an application thereof in the preparation of a drug for the treatment or prevention of RORγ-regulated diseases; more importantly, such a compound can also be used in the preparation of a drug for the treatment of inflammation, immune diseases, cancer and neurological diseases.

IPC Classes  ?

• C07C 315/04 - Preparation of sulfonesPreparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided is a composition and an application thereof. The composition is used to prepare a medium for inducing differentiation of human pluripotent stem cells to liver precursor cells. By means of screening active components, optimizing the composition ratio and adding a GSK3-beta inhibitor, a Nodal activator, a BMP activator, a BMP inhibitor and a Hedgehog activator, human pluripotent stem cells are induced to differentiate to liver precursor cells. The process is simple and efficient, the content of positive cells is high, and the cost of cell differentiation is reduced. The invention can be used for research and application in drug development and regenerative medicinal treatment, and has broad application prospects.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

Provided are a culture medium for screening and expanding liver stem cells and a use thereof. On the basis of the colony-forming capacity of stem cells, a culture medium has definite components is developed by performing optimized combination on small chemical compounds and cytokines in a culture medium for screening and by skipping cell surface antigen marker flow sorting. The optimized culture medium can screen, separate and expand adult liver stem cells having a liver/gall bidirectional differentiation potential directly from an adult liver.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• A61K 35/407 - LiverHepatocytes

Abstract

Provided are a culture medium for expanding and cultivating human liver progenitor cells and an application thereof. The chemical components of the formula of the described culture medium are clear, no serum is present, and various components thereof cooperate with each other to synergize. The culture medium is used for the long-term expansion and cultivation of liver progenitor cells in vitro and is used for maintaining the dryness thereof, is beneficial in quickly and efficiently obtaining a large number of functional liver cells, and is suitable for clinical hepatocyte transplantation application as well as for the use of hepatocyte reactors in bioartificial livers.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61L 27/38 - Animal cells

Abstract

Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• C07D 487/04 - Ortho-condensed systems

Abstract

Provided in the present invention are pharmaceutically acceptable salts of a compound, N-((5-((5-chloro-4-((naphthalen-2-yl)amino))pyrimidin-2-yl)amino)-2-((N-methyl-N- dimethylaminoethyl)amino)-4-methoxyphenyl)acrylamide, especially phosphates, sulfates, hydrobromides and camphorsulfonates, and a use of the salts in the preparation of drugs for treating or preventing tumors.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• A61K 9/36 - Organic coatings containing carbohydrates or derivatives thereof
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is a culture system for chemically inducing the generation of pluripotent stem cells, which culture system comprises a basic culture medium and a composition for promoting chemical reprogramming, wherein the composition for promoting chemical reprogramming contains a thymine analog, a cAMP activator, a TGF-β receptor inhibitor, a bone morphogenetic protein, an RA receptor activator, a GSK3 inhibitor and a basic fibroblast growth factor, wherein the culture system does not contain serum. In the process of chemically reprogramming somatic cells by means of the method provided herein, there is no need to frequently separate disks of cells, simplifying the operation steps and reducing the cell loss occurred during a disk-separating process compared to existing culture methods, and the use of the culture system provided herein does not require serum, further simplifying the subsequent collection and molecular mechanism analysis of pluripotent stem cells, and further facilitating subsequent establishment of an animal origin-free culture system for inducing pluripotent stem cells.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Disclosed is a T cell receptor (TCR) having the property of binding to ILSPFLPLL-HLA A2 complex. The binding affinity of the TCR to the ILSPFLPLL-HLA A2 complex is at least 1.3 times the binding affinity of wild-type TCR to the ILSPFLPLL-HLA A2 complex. The TCRs can be used alone or associated with a therapeutic agent for targeting ILSPFLPLL-HLA A2 complex-presenting tumor cells.

IPC Classes  ?

• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus

Abstract

Mycobacterium ulceransMycobacterium marinumMycobacterium lepraeMycobacterium leprae, and said compounds also have the advantages of convenient use, quick effect, low dosage, low toxic side effects, etc.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 31/04 - Antibacterial agents
• A61P 31/08 - Antibacterial agents for leprosy

Abstract

Provided are multipotent stem cells comprising a Runx1 and Hoxa9 tandem co-expression vector, and differentiated T-cells and the use thereof. By introducing an exogenous Runx1 and Hoxa9 co-expression vector into a multipotent stem cell, the multipotent stem cells that inductively co-express the exogenous Runx1 and Hoxa9 have been successfully constructed, and the multipotent stem cells are directed to differentiate into T-lineage progenitor cells and will develop into T-cells. The multipotent stem cell-derived T-cells obtained by means of the method not only have normal functions, but also have no tumorigenic risk.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 37/04 - Immunostimulants
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are an artificial polypeptide, a method of obtaining the polypeptide, an artificial nucleic acid encoding the polypeptide, a construct containing the nucleic acid, and a method of cell fate conversion.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/867 - Retroviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided are an artificial polypeptide, a method of obtaining the polypeptide, an artificial nucleic acid encoding the polypeptide, a construct containing the nucleic acid, and a method of cell fate conversion.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/867 - Retroviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided is a genetically engineered γδT cell, which is characterized in that a high-affinity αβTCR gene is transferred into the γδT cell, and the affinity of the high-affinity αβTCR to the specific pMHC thereof is at least two times of that of a wild-type αβTCR corresponding thereto. Further provided are a use of and a preparation method for the γδT cell.

IPC Classes  ?

• C12N 5/22 - Human cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a method for rebuilding a marrow microenvironment in a testee whose marrow microenvironment is damaged. The method comprises: implanting a composition containing separated mesenchymal stromal cells (MSC) into a marrow cavity of a testee. By means of the method in the present invention, the marrow microenvironment is rebuilt, the normal marrow hematopoiesis function is recovered, the leukemia pathology progress is inhibited/delayed, and the survival period is obviously prolonged. In addition, the method in the present invention can be used for treating blood tumors such as leukemia and Aplastic anemia (AA) and has the advantages of being safe, effective and free of side effects.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/00 - Antineoplastic agents
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention discloses a method for remolding bone marrow microenvironment in a subject having an impaired bone marrow microenvironment, which comprises implanting a composition comprising isolated mesenchymal stromal cells (MSCs) into the bone marrow cavity of the subject. The method of the present invention successfully remolds the bone marrow microenvironment, recovers the normal hematopoiesis of bone marrow, inhibits/delays the pathological process of leukemia and significantly prolongs the survival period. In addition, the method according to the present invention can be used for the treatment of hematologic tumors such as leukemia and aplastic anemia (AA), which is safe and effective but has no side effects.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61P 7/06 - Antianaemics
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicylaldehyde with multiple substituent groups is synthesized through a plurality of steps by using sulfur pentafluoride phenol as a raw material, and then the sulfur pentafluoride substituted benzopyran compound is synthesized on this basis. The method is simple and convenient, and low in cost; overcomes the defects that, at present, the number of types of sulfur pentafluoride phenols is small, and the synthesis of various sulfur pentafluoride substituted benzopyran compounds cannot be met; and has wide industrial application prospects.

IPC Classes  ?

• C07D 311/70 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07C 319/00 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides
• C07C 323/20 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• C07C 319/20 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Abstract

Provided is a method for directional differentiation of human pluripotent stem cells. The method comprises cultivating human pluripotent stem cells in a clearly-composed cell culture environment without exogenous hematopoietic cytokines, serum or stromal cells, and after the formation of the embryoid body, adding vascular endothelial growth factors and bone morphogenetic protein 4 and attaching the embryoid body to the surface covered with collagen IV to induce mesoderm differentiation, thereby generating hematopoietic progenitor cells and blood cells.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0789 - Stem cellsMultipotent progenitor cells

Abstract

Provided are an indole compound and an application thereof. The compound is capable of effectively inhibiting CBP/EP300 bromodomain receptors, and may be used as a drug for cancers, inflammatory diseases, autoimmune diseases, septicaemia and viral infections.

IPC Classes  ?

• C07D 243/36 - Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings containing an indole or hydrogenated indole ring system
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

Abstract

Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain and extra-terminal domain (BET) bromodomain receptor inhibitors. The group of compounds may effectively inhibit the bromodomain of BET family proteins, thereby blocking the interaction between BET family proteins and chromatin histones, thus regulating gene transcription, causing changes in downstream signal paths, and having a significant impact on many diseases. The present invention is effective in the treatment of tumors, and may also improve the treatment of other diseases, thus having broad application prospects.

IPC Classes  ?

• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators

Abstract

The present invention relates to a method for inducing the transdifferentiation of B lymphoid cells into T lymphoid cells using transcription factor Hoxb5, and related products and applications thereof. The method of the present invention specifically comprises: introducing Hoxb5, a nucleic acid molecule encoding Hoxb5 or a construct comprising the nucleic acid molecule into the B lymphoid cells to obtain the B lymphoid cells with overexpressed Hoxb5; then implanting the obtained B lymphoid cells into the body of a subject to obtain regenerated T cell progenitor cells by way of transdifferentiation, and then the T cell progenitor cells differentiate into mature T cells with functions. The regenerated T cells obtained using the method of the present invention are not only functionally normal, but also show no risk of tumorigenesis or extremely low risk of tumorigenesis.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/867 - Retroviral vectors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

Provided are an artificial polypeptide and a method for obtaining the same, as well as an artificial nucleic acid encoding the polypeptide and a construct containing the nucleic acid. Also provided is a method of cell fate conversion.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
• C12N 15/12 - Genes encoding animal proteins
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, cornal ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition comprising N-((5-((5-chloro-4-((naphthalene -2-yl)amino))pyrimidine-2-yl)amino)-2-((N-methyl-N-dimethylaminoethyl)amino)-4-methoxypheny)acrylamide, and a preparation method for the pharmaceutical composition.

IPC Classes  ?

• C07D 239/46 - Two or more oxygen, sulfur or nitrogen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Disclosed is a method of genetical alternation and disease modeling using a cre-dependent cas9 expressing mammal. The transgenic mammal whose genome comprises a polynucleotide sequence, which comprises a polynucleotide encoding Cas9, a first pair of loxP sequences inverted in orientation to each other, and a second pair of loxP sequences inverted in orientation to each other.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 9/22 - Ribonucleases

Abstract

Provided are a method for inducing the transdifferentiation of B lymphoid cells into T lymphoid cells using a transcription factor Hoxb5, a related product and the use thereof. The method particularly comprises: introducing Hoxb5, a nucleic acid molecule encoding Hoxb5, or a construct comprising the nucleic acid molecule into the B lymphoid cell to obtain a Hoxb5 over-expressing B lymphoid cell; and implanting the obtained B lymphoid cell into a subject, obtaining a regenerated T cell progenitor cell by means of transdifferentiation, and differentiating the T cell progenitor cell to obtain a mature and functional T lymphoid cell.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Genetically humanized mammals expressing human albumin and uses thereof. In some embodiments, the genome of the non-human transgenic mammal includes a polynucleotide sequence encoding human albumin, which may include a modification of human albumin gene.

IPC Classes  ?

• C12N 15/14 - Human serum albumins
• C07K 14/765 - Serum albumin, e.g. HSA

Abstract

Provided is are a T cell receptor (TCR) capable of specific binding of short-chain polypeptide VFSTVPPAFI derived from a SAGE1 antigen, a nucleic acid molecule coding the TCR, a vector comprising the nucleic acid molecule, and a cell transducing the TCR. The antigen short-chain polypeptide VFSTVPPAFI can form a complex with HLA A2402 and be transduced together to cell surface.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/867 - Retroviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

The invention provides a truncated MICA (MHC class Ⅰ-related chain A), i.e., a DMIC molecule, with high stability and affinity, and a preparation method and application thereof. The hydrophobic core region of the DMIC molecule of the present invention has been mutated, increasing stability and affinity.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents

Abstract

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

IPC Classes  ?

• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections.

IPC Classes  ?

• C07D 209/92 - Naphthostyrils
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides a polycrystalline form of a 2-aminopyrimidine. The invention specifically provides N-((5-((5-chloro-4-((naphth-2-yl)amino))pyrimidin-2-yl)amino)-2-((N-methyl-N-dimethylaminoethyl)amino)-4-methoxybenzyl)acrylamide, a polycrystalline form thereof, and a manufacturing method and application of same.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Abstract

Provided are a mycobacteriophage capable of delivering an autonomous luminescent element and a use thereof. The mycobacteriophage contains a gene LuxCDABE needed for the autonomous luminescence in a host bacterium. The autonomous luminescent element is present on a transposon and can be randomly inserted into the genome of the host bacterium along with the transposable element. The mycobacteriophage can be used to rapidly diagnose live host bacteria in a sample and to rapidly detect the sensitivity of the host bacteria to a drug.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12R 1/92 - Viruses
• C12R 1/32 - Mycobacterium

Abstract

Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicylaldehyde with multiple substituent groups is synthesized through a plurality of steps by using sulfur pentafluoride phenol as a raw material, and then the sulfur pentafluoride substituted benzopyran compound is synthesized on this basis. The method is simple and convenient, and low in cost; overcomes the defects that, at present, the number of types of sulfur pentafluoride phenols is small, and the synthesis of various sulfur pentafluoride substituted benzopyran compounds cannot be met; and has wide industrial application prospects.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07C 323/20 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• C07C 319/00 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides

Abstract

The present invention falls within the field of chemical pharmaceutical techniques, and in particular provides the preparation of a tetrahydroquinoline-related bicyclic compound and use thereof, wherein the compound has the structure as shown in formula I. The compound and a pharmaceutically acceptable salt, an isomer, a racemate, a prodrug co-crystal complex, a hydrate and a solvate thereof can effectively regulate ROR receptors, and can be used to prepare drugs for treating related diseases regulated by ROR receptors, or can be used to prepare drugs for treating cancers, inflammatory diseases and autoimmune diseases.

IPC Classes  ?

• C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
• C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 215/38 - Nitrogen atoms
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.

IPC Classes  ?

• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Provided is a differentiation medium capable of inducing ES cells and/or iPS cells into neural stem cells. The differential medium is a conventional medium comprising 1% of N2 additive, the conventional medium being at least one of RPMI1640 medium, DMEM/F12 medium, high glucose DMEM medium and á-MEM medium. Also provided are a use of the differential medium in the preparation of neural stem cells and a method for preparing neural stem cells. ES cells and/or iPS cells can be rapidly and stably induced into neural stem cells by using the differential medium.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells
• C12N 5/0793 - Neurons
• C12N 5/079 - Neural cells

Abstract

Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided is a method for controlling differentiation of multipotent stem cells into endoderm-derived cells, and particularly for preventing, by using a TGF inhibitor or an SNAI1 inhibitor, differentiation of multipotent stem cells into the endoderm-derived cells.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

Provided are a primary cell culture medium, use thereof for culturing a human primary cell in vitro, and method for utilizing the culture medium to culture a human primary B-cell acute lymphoblastic leukemia (B-ALL) cell in vitro. The primary cell culture medium comprises a base culture medium and cell factors: human FLT3L, human IGFl, human IL-7 and human IL-6, and is serum-free.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula I, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes.

IPC Classes  ?

• C07D 277/40 - Unsubstituted amino or imino radicals
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and a use thereof. The compound and a pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell-proliferation disorders, inflammatory diseases and autoimmune diseases, septicemia, and viral infections.

IPC Classes  ?

• C07D 209/92 - Naphthostyrils
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

This invention provides compounds and compositions for inducing mesenchymal stem cells into chondrocytes ex vivo and in vivo. The compound could lead to a stem cell-based therapy for osteoarthritis and joint injuries. The present invention also provides the preparation method of the compounds of the present invention, the use of the compound and the method to treat osteoarthritis and joint injuries.

IPC Classes  ?

• C07D 277/06 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 237/10 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 265/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention discloses coupling compounds of a structure as shown in Formula I, II or III formed by connecting NSAID anti-inflammatory and analgesic drugs and EGFR inhibitors by ester bonds or pharmaceutically acceptable salts or stereoisomers thereof or prodrug molecules thereof: where R is a NSAID anti-inflammatory and analgesic drug. In the present invention, the coupling compounds obtained by coupling NSAID anti-inflammatory and analgesic drugs with EGFR inhibitors have excellent therapeutic effects of tumors and provide new drugs for clinic treatment options.

IPC Classes  ?

• C07D 239/94 - Nitrogen atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Abstract

Provided is a T cell receptor (TCR) capable of combining peptide derived from Epstein barr virus (EB virus) latent membrane protein (LMP-2). The peptide is presented in the form of a SSCSSCPLSK-HLA A1101 compound. Also provided are a nucleic acid molecule for encoding the TCR, carrier comprising the nucleic acid molecule, and cell for transferring the TCR.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/86 - Viral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a nicotinamide phosphate transferase (Nampt) inhibitor as represented by formula I, and preparation method and application thereof. Raw material for synthesis of the Nampt is inexpensive, and the synthesis of the Nampt has a convenient route and a simple operation and is suitable for industrial production, and an obtained compound has antitumor activity, thus being hopeful of being developed into antitumor drugs.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07D 213/56 - Amides
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

IPC Classes  ?

• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Abstract

The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F12 medium; N2 supplement; retinoic acid; and BMP-4.

IPC Classes  ?

• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• C12N 5/074 - Adult stem cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• C07K 14/51 - Bone morphogenic factorOsteogeninOsteogenic factorBone-inducing factor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Disclosed are small molecules of formula (I) which can inhibit WNT secretion from a cell or restore mutant P53 function in a cell, pharmaceutical compositions and their use in the treatment of abnormal conditions, such as malignant tumors.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are a UCP1-luciferase (uncoupling protein 1-luciferase) gene knock-in non-human mammal model and a construction method and use thereof. The UCP1-luciferase (uncoupling protein 1-luciferase) gene knock-in non-human mammal model can serve as a screening platform of white fat cell browning drugs, and simple, rapid and large-scale screening on drugs for regulating and controlling the expression of UCP1 can be realized; and on the premise that the non-human mammal is not hurt, the expression and distribution of the UCP1 can be directly subjected to bio-assay by utilizing a fluorescent imager.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided in the present invention are a compound having a structural feature of the general formula I as a novel retinoic acid orphan nuclear receptor γ subtype (RORγ) inhibitor, and the uses of the compound and a pharmaceutically acceptable salt, isomer, racemate, prodrug co-crystallizing complex, hydrate and solvate in the drug for treating or preventing a disease associated with RORγ regulation and control.

IPC Classes  ?

• C07D 209/92 - Naphthostyrils
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 17/06 - Antipsoriatics
• A61P 11/06 - Antiasthmatics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are a method for preparing an induced pluripotent stem cell and a composition used in the method. The method comprises: introducing a composition for promoting the formation of an induced pluripotent stem cell into a somatic cell, the composition comprising: (i) a c-Jun antagonist and one group of factors from among the following seven such groups: (1) Sox2, Klf4 and c-Myc, (2) Klf4 and c-Myc, (3) Oct3/4, Klf4 and c-Myc, (4) Sox2, Nanog and Lin28, (5) Oct3/4, Nanog and Lin28, (6) Oct3/4, Klf and Sox2, and (7) Klf4 and Sox2; or (ii) the c-Jun antagonist, Jhdm1b and Id1, and at least one of Glis1, Sall4 or Lrh1; or (iii) the c-Jun antagonist, Jhdm1b and Id1, and at least one of: Oct4, Klf4, Sox2, Lin28, Esrrb, Lef1, Utf1 or miRNA C. The present method allows for successful preparation of induced pluripotent stem cells with no generation of abnormal chromosomes.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Disclosed are synthetic mitochondria obtained by introducing exogenous DNA into mitochondria or mitochondrial shells. Cells containing exogenous mitochondria are then obtained by introducing the synthetic mitochondria into mammalian cells via endocytosis, thereby allowing the exogenous mitochondria to perform effectively within the cells. After being introduced, synthetic mitochondrial DNA genes can be expressed stably, and passaged effectively. The method for introducing exogenous mitochondria into cells can serve as a new mitochondrial molecular cloning method, performing gene knockout, gene knock-in, gene rearrangement etc. within mitochondria, thereby enabling any molecular cloning of mammalian mitochondrial DNA to be engineered, which has significant implications for the treatment of diseases caused by mitochondrial DNA mutations.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided in the present invention is a composition for promoting the transdifferentiation of fibroblasts into adipocytes, the onset factors thereof being a hepatocyte growth factor, epidermal growth factor, dexamethasone and insulin. Also provided in the present invention is a culture solution and a method for inducing the transdifferentiation of fibroblasts into adipocytes.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0797 - Stem cellsProgenitor cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells